

Ted Wun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/662028/publications.pdf>

Version: 2024-02-01

217
papers

8,422
citations

44069

48
h-index

51608

86
g-index

219
all docs

219
docs citations

219
times ranked

9013
citing authors

#	ARTICLE	IF	CITATIONS
1	Early mortality and survival improvements for adolescents and young adults with acute promyelocytic leukemia in California: an updated analysis. <i>Haematologica</i> , 2022, 107, 733-736.	3.5	2
2	The incidence of cancer-associated thrombosis is increasing over time. <i>Blood Advances</i> , 2022, 6, 307-320.	5.2	46
3	Biomarker signatures in cancer patients with and without venous thromboembolism events: a substudy of CASSINI. <i>Blood Advances</i> , 2022, 6, 1212-1221.	5.2	9
4	Incidence and Outcomes Associated with 6,841 Isolated Distal Deep Vein Thromboses in Patients with 13 Common Cancers. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1407-1414.	3.4	7
5	Second primary malignancy risk after Hodgkin lymphoma treatment among HIV-uninfected and HIV-infected survivors. <i>Leukemia and Lymphoma</i> , 2022, , 1-11.	1.3	1
6	Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. <i>JCO Oncology Practice</i> , 2022, 18, e586-e599.	2.9	9
7	Racial disparities in cancer-associated thrombosis. <i>Blood Advances</i> , 2022, 6, 3167-3177.	5.2	14
8	Treatment at Specialized Cancer Centers Is Associated with Improved Survival in Adolescent and Young Adults with Soft Tissue Sarcoma. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 370-378.	1.3	6
9	COVID-19 and venous thromboembolism risk in patients with sickle cell disease. <i>Blood Advances</i> , 2022, 6, 4408-4412.	5.2	5
10	Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients. <i>Blood Cancer Journal</i> , 2021, 11, 5.	6.2	11
11	Impact of location of inpatient cancer care on patients with Ewing sarcoma and osteosarcoma—A population-based study. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28998.	1.5	4
12	Urban—Rural Variations in Quality of Care Among Patients With Cancer in California. <i>American Journal of Preventive Medicine</i> , 2021, 61, e279-e288.	3.0	10
13	COVID-19 Testing for Underserved and Vulnerable Populations: The NIH Rapid Acceleration Of Diagnostics (RADx) Initiative, Experiences from the field. <i>ISEE Conference Abstracts</i> , 2021, 2021, .	0.0	1
14	Building an institutional K awardee program at UC Davis through utilization of CTSA resources. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e171.	0.6	1
15	Pregnancy Outcomes in Women with Sickle Cell Disease in California: A Retrospective Cohort Study. <i>Blood</i> , 2021, 138, 489-489.	1.4	1
16	Stage at diagnosis and survival among adolescents and young adults with lymphomas following the Affordable Care Act implementation in California. <i>International Journal of Cancer</i> , 2021, , .	5.1	4
17	Safety of light emitting diode—red light on human skin: Two randomized controlled trials. <i>Journal of Biophotonics</i> , 2020, 13, e201960014.	2.3	14
18	Splenectomy and the incidence of venous thromboembolism and sepsis in patients with autoimmune hemolytic anemia. <i>Blood Cells, Molecules, and Diseases</i> , 2020, 81, 102388.	1.4	19

#	ARTICLE	IF	CITATIONS
19	Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality. TH Open, 2020, 04, e309-e317.	1.4	5
20	Impact of insurance type and timing of Medicaid enrollment on survival among adolescents and young adults with cancer. Pediatric Blood and Cancer, 2020, 67, e28498.	1.5	13
21	Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. American Journal of Hematology, 2020, 95, 1066-1074.	4.1	24
22	Treatment Complications and Survival Among Children and Young Adults With Acute Lymphoblastic Leukemia. JCO Oncology Practice, 2020, 16, e1120-e1133.	2.9	13
23	Chronic medical conditions and late effects following non-Hodgkin lymphoma in HIV-uninfected and HIV-infected adolescents and young adults: a population-based study. British Journal of Haematology, 2020, 190, 371-384.	2.5	10
24	High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. Leukemia and Lymphoma, 2020, 61, 2605-2613.	1.3	4
25	Homocysteine is associated with severity of microvasculopathy in sickle cell disease patients. British Journal of Haematology, 2020, 190, 450-457.	2.5	7
26	Bleeding in patients with sickle cell disease: a population-based study. Blood Advances, 2020, 4, 793-802.	5.2	20
27	Disparities in the Occurrence of Late Effects following Treatment among Adolescent and Young Adult Melanoma Survivors. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2195-2202.	2.5	9
28	Early Initiation of Treatment with Rivipansel for Acute Vaso-Occlusive Crisis in Sickle Cell Disease (SCD) Achieves Earlier Discontinuation of IV Opioids and Shorter Hospital Stay: Reset Clinical Trial Analysis. Blood, 2020, 136, 18-19.	1.4	9
29	Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. JMIR Research Protocols, 2020, 9, e16319.	1.0	19
30	Measuring the Impact of COVID-19 on Hematology-Oncology Trainees: A Quantitative and Qualitative Assessment. Blood, 2020, 136, 20-21.	1.4	3
31	Racial/Ethnic Disparities in Cancer-Associated Thrombosis: A Population-Based Study. Blood, 2020, 136, 53-55.	1.4	0
32	Second Primary Malignancy Risk Among HIV-Uninfected and HIV-Infected Survivors of Hodgkin Lymphoma: A 30-Year Follow-up Population-Based Study. Blood, 2020, 136, 15-17.	1.4	1
33	Utility of Inferior Vena Cava Filter in the Management of Venous Thromboembolism Among Patients with Brain Metastases: A Population-Based Study. Blood, 2020, 136, 47-48.	1.4	0
34	Disparities in the Use of Allogeneic Hematopoietic Stem Cell Transplant Among Children, Adolescents, and Young Adults with Acute Leukemia in California. Blood, 2020, 136, 4-5.	1.4	1
35	Association Between Autologous Stem Cell Transplant and Survival Among Californians With Multiple Myeloma. Journal of the National Cancer Institute, 2019, 111, 78-85.	6.3	20
36	A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia. American Journal of Hematology, 2019, 94, E291-E294.	4.1	11

#	ARTICLE	IF	CITATIONS
37	Biomarkers of Cancer-Associated Thromboembolism. <i>Cancer Treatment and Research</i> , 2019, 179, 69-85.	0.5	7
38	Detecting opioid metabolites in exhaled breath condensate (EBC). <i>Journal of Breath Research</i> , 2019, 13, 046014.	3.0	10
39	High incidence of venous thromboembolism recurrence in patients with sickle cell disease. <i>American Journal of Hematology</i> , 2019, 94, 862-870.	4.1	19
40	Unplanned Hospitalization Among Individuals With Cancer in the Year After Diagnosis. <i>Journal of Oncology Practice</i> , 2019, 15, e20-e29.	2.5	37
41	The Epidemiology of Cancer-Associated Venous Thromboembolism: An Update. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 321-325.	2.7	67
42	Impact of Health Insurance on Stage at Cancer Diagnosis Among Adolescents and Young Adults. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1152-1160.	6.3	32
43	Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 720-728.	27.0	520
44	Decreased Early Mortality in Young Adult Patients With Acute Lymphoblastic Leukemia Treated at Specialized Cancer Centers in California. <i>Journal of Oncology Practice</i> , 2019, 15, e316-e327.	2.5	8
45	Cancer specific survival in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2019, 185, 128-132.	2.5	5
46	Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27426.	1.5	38
47	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , 2019, 4, .	5.0	110
48	Upper extremity deep venous thrombosis in 10 common malignancies: Analysis of incidence, risk factors, and effect on mortality from the California Cancer Registry.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18190-e18190.	1.6	4
49	Worse outcomes associated with public insurance at sarcoma diagnosis in adolescent and young adults (AYAs).. <i>Journal of Clinical Oncology</i> , 2019, 37, e18143-e18143.	1.6	0
50	Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Non-Hodgkin's Lymphoma: Analysis of the California Cancer Registry. <i>Blood</i> , 2019, 134, 932-932.	1.4	0
51	Sociodemographic disparities in the occurrence of medical conditions among adolescent and young adult Hodgkin lymphoma survivors. <i>Cancer Causes and Control</i> , 2018, 29, 551-561.	1.8	38
52	Decreased early mortality associated with the treatment of acute myeloid leukemia at National Cancer Institute-designated cancer centers in California. <i>Cancer</i> , 2018, 124, 1938-1945.	4.1	40
53	Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California. <i>Leukemia and Lymphoma</i> , 2018, 59, 2482-2484.	1.3	2
54	Cardiovascular disease incidence in adolescent and young adult cancer survivors: a retrospective cohort study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 388-397.	2.9	39

#	ARTICLE	IF	CITATIONS
55	Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 498.e1-498.e7.	1.6	2
56	The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. <i>American Journal of Hematology</i> , 2018, 93, E391-E395.	4.1	52
57	How I diagnose and treat venous thromboembolism in sickle cell disease. <i>Blood</i> , 2018, 132, 1761-1769.	1.4	29
58	Cancer associated venous thromboembolism: incidence and impact on survival. <i>Thrombosis Research</i> , 2018, 164, S178-S179.	1.7	5
59	Complications and early mortality in patients with acute promyelocytic leukemia treated in California. <i>American Journal of Hematology</i> , 2018, 93, E370-E372.	4.1	11
60	Rivaroxaban Thromboprophylaxis in High-Risk Ambulatory Cancer Patients Receiving Systemic Therapy: Results of a Randomized Clinical Trial (CASSINI). <i>Blood</i> , 2018, 132, LBA-1-LBA-1.	1.4	12
61	Targeting Protein Disulfide Isomerase with the Oral Flavonoid Isoquercetin Prevents Venous Thromboembolism in Advanced Cancer: Results of a Multi-Dose, Multi-Center, Phase II Clinical Trial (CATIQ Study). <i>Blood</i> , 2018, 132, 985-985.	1.4	0
62	Inpatients Costs of Cancer Treatment Among Children and Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated at Specialized Cancer Centers in California. <i>Blood</i> , 2018, 132, 324-324.	1.4	0
63	Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time. <i>Blood</i> , 2018, 132, 3598-3598.	1.4	0
64	Worse Outcomes Associated with Public Insurance in AYAs with Leukemia and Lymphoma. <i>Blood</i> , 2018, 132, 977-977.	1.4	0
65	Episodes of High Emergency Department Utilization Among a Cohort of Persons Living with Sickle Cell Disease. <i>Blood</i> , 2018, 132, 159-159.	1.4	8
66	Medical Conditions Among Survivors of Adolescent and Young Adult Non-Hodgkin Lymphoma (NHL), Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 839-839.	1.4	1
67	Incidence and Outcomes Associated with Distal Deep Vein Thrombosis in 760,344 Patients with 13 Common Malignancies. <i>Blood</i> , 2018, 132, 2526-2526.	1.4	0
68	Incidence of Bleeding in Patients with Sickle Cell Disease: A Population Based Study. <i>Blood</i> , 2018, 132, 10-10.	1.4	3
69	Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: A randomized trial. <i>Thrombosis Research</i> , 2017, 151, 89-95.	1.7	109
70	Early mortality and complications in hospitalized adult Californians with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2017, 177, 791-799.	2.5	43
71	Increased incidence of <sc>VTE</sc> in sickle cell disease patients: risk factors, recurrence and impact on mortality. <i>British Journal of Haematology</i> , 2017, 178, 319-326.	2.5	87
72	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: A population-based study. <i>Thrombosis Research</i> , 2017, 153, 57-64.	1.7	33

#	ARTICLE	IF	CITATIONS
73	Increased risk of leukemia among sickle cell disease patients in California. <i>Blood</i> , 2017, 130, 1597-1599.	1.4	95
74	Selectin catch-bonds mechanotransduce integrin activation and neutrophil arrest on inflamed endothelium under shear flow. <i>Blood</i> , 2017, 130, 2101-2110.	1.4	69
75	MP15-06 ASSESSMENT OF QUALITY OF CARE IN NON-MUSCLE INVASIVE BLADDER CANCER: UPTAKE OF RE-RESECTION FOR HIGH GRADE OR T1 BLADDER TUMORS IN CALIFORNIA. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
76	PD19-04 IMMEDIATE INTRAVESICAL CHEMOTHERAPY FOR LOW GRADE BLADDER TUMORS IN CALIFORNIA: AN UNDERUTILIZED PRACTICE AND ITS IMPACT ON RECURRENCE. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
77	Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2135-2145.	3.4	53
78	Osteonecrosis of the femoral head in sickle cell disease: prevalence, comorbidities, and surgical outcomes in California. <i>Blood Advances</i> , 2017, 1, 1287-1295.	5.2	55
79	Secondary acute lymphoblastic leukemia is a distinct clinical entity with prognostic significance. <i>Blood Cancer Journal</i> , 2017, 7, e605-e605.	6.2	22
80	Emergency department use by recently diagnosed cancer patients in California. <i>Journal of Community and Supportive Oncology</i> , 2017, 15, 95-102.	0.1	16
81	Incidence of Venous Thromboembolism and Impact on Mortality in Patients with Primary CNS Lymphoma: A Population Based Study. <i>Blood</i> , 2017, 130, 754-754.	1.4	3
82	Sickle cell disease: an inherited thrombophilia. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 640-647.	2.5	42
83	Outcomes After Vena Cava Filter Use in Noncancer Patients With Acute Venous Thromboembolism. <i>Circulation</i> , 2016, 133, 2018-2029.	1.6	68
84	Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE): patterns of use and outcomes. <i>Thrombosis Research</i> , 2016, 140, S132-S141.	1.7	23
85	A single-blind, dose escalation, phase I study of high-fluence light-emitting diode-red light (LED-RL) on human skin: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 385.	1.6	4
86	Lectin-like oxidized low-density lipoprotein receptor (LOX-1) in sickle cell disease vasculopathy. <i>Blood Cells, Molecules, and Diseases</i> , 2016, 60, 44-48.	1.4	7
87	Osteonecrosis of the Femoral Head in Sickle Cell Disease: Prevalence, Comorbidities and Surgical Outcomes in California. <i>Blood</i> , 2016, 128, 2489-2489.	1.4	23
88	Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM). <i>Blood</i> , 2016, 128, 846-846.	1.4	3
89	Time to Treatment Initiation Predicts Overall Survival in Hospitalized Acute Myeloid Leukemia (AML) Patients: A California Population-Based Study. <i>Blood</i> , 2016, 128, 3982-3982.	1.4	2
90	Adolescent and Young Adult Oncology Patients with Acute Lymphoblastic Leukemia: Shifting Location of Care over Time. <i>Blood</i> , 2016, 128, 2375-2375.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Sociodemographic Factors Predict Medical Conditions Among Five-Year Survivors of Adolescent and Young Adult Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 693-693.	1.4	0
92	Decreased Early Mortality Associated with Treatment of Acute Myeloid Leukemia (AML) at NCI-Designated Cancer Centers in California. <i>Blood</i> , 2016, 128, 391-391.	1.4	0
93	Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. <i>Blood</i> , 2015, 125, 2656-2664.	1.4	178
94	Vena Cava Filter Use in Cancer Patients with Acute Venous Thromboembolism in California. <i>Thrombosis Research</i> , 2015, 135, 809-815.	1.7	11
95	Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact. <i>Blood</i> , 2015, 126, 1305-1305.	1.4	0
96	The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment. <i>Blood</i> , 2015, 126, 1991-1991.	1.4	0
97	Phase 1 Study of the E-Selectin Inhibitor GMI 1070 in Patients with Sickle Cell Anemia. <i>PLoS ONE</i> , 2014, 9, e101301.	2.5	64
98	Adverse Impact of Venous Thromboembolism on Patients with Cancer. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 313-318.	2.7	8
99	Multiplexed measurements of immunomodulator levels in peripheral blood of healthy subjects: Effects of analytical variables based on anticoagulants, age, and gender. , 2014, 86, 426-435.		22
100	Pattern of Frequent But Nontargeted Pharmacologic Thromboprophylaxis for Hospitalized Patients With Cancer at Academic Medical Centers: A Prospective, Cross-Sectional, Multicenter Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1792-1796.	1.6	45
101	Role of the Hemostatic System on Sickle Cell Disease Pathophysiology and Potential Therapeutics. <i>Hematology/Oncology Clinics of North America</i> , 2014, 28, 355-374.	2.2	38
102	Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): A California Cancer Registry analysis. <i>Lung Cancer</i> , 2014, 85, 264-269.	2.0	68
103	Lymphoma and venous thromboembolism: influence on mortality. <i>Thrombosis Research</i> , 2014, 133, S23-S28.	1.7	38
104	Pan-Selectin Antagonist Rivipansel (GMI-1070) Reduces Soluble E-Selectin Levels While Improving Clinical Outcomes in SCD Vaso-Occlusive Crisis. <i>Blood</i> , 2014, 124, 2704-2704.	1.4	4
105	A Phase 3 Study of L-Glutamine Therapy for Sickle Cell Anemia and Sickle Cell α -Thalassemia. <i>Blood</i> , 2014, 124, 86-86.	1.4	25
106	A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era. <i>Blood</i> , 2014, 124, 2609-2609.	1.4	0
107	A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. <i>Journal of Hematology and Oncology</i> , 2013, 6, 17.	17.0	62
108	Biomolecular markers of cancer-associated thromboembolism. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 19-29.	4.4	31

#	ARTICLE	IF	CITATIONS
109	The Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS). <i>Advanced Emergency Nursing Journal</i> , 2013, 35, 143-153.	0.5	6
110	High Variation Between Hospitals in Vena Cava Filter Use for Venous Thromboembolism. <i>JAMA Internal Medicine</i> , 2013, 173, 506.	5.1	68
111	Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia. <i>Blood</i> , 2013, 121, 4782-4790.	1.4	174
112	An Analysis Of The Pediatric Sub-Group From The Phase 2 Study Of GMI 1070 – A Novel Agent For The Vaso-Occlusive Crisis Of Sickle Cell Anemia. <i>Blood</i> , 2013, 122, 2206-2206.	1.4	2
113	Effects Of GMI 1070, a Pan-Selectin Inhibitor, On Pain Intensity and Opioid Utilization In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 775-775.	1.4	2
114	GMI 1070: Reduction In Time To Resolution Of Vaso-Occlusive Crisis and Decreased Opioid Use In a Prospective, Randomized, Multi-Center Double Blind, Adaptive Phase 2 Study In Sickle Cell Disease. <i>Blood</i> , 2013, 122, 776-776.	1.4	7
115	Pharmacologic Thromboprophylaxis Is Frequently Prescribed In Hospitalized Cancer Patients At Academic Medical Centers: A Prospective, Cross-Sectional, Multi-Center Study. <i>Blood</i> , 2013, 122, 2374-2374.	1.4	0
116	Predictors Of Vena Cava Filter Use For Venous Thromboembolism In Cancer Patients. <i>Blood</i> , 2013, 122, 935-935.	1.4	0
117	Outcomes After Vena Cava Filter Placement In Cancer Patients Hospitalized For Acute Venous Thromboembolism. <i>Blood</i> , 2013, 122, 936-936.	1.4	0
118	The US Initiative: Clinical and Translational Science Awards – The UC Davis Perspective. <i>Translational Research in Biomedicine</i> , 2012, , 18-28.	0.4	0
119	Exchange Transfusion Therapy and Its Effects on Real-time Microcirculation in Pediatric Sickle Cell Anemia Patients. <i>Journal of Pediatric Hematology/Oncology</i> , 2012, 34, 169-174.	0.6	13
120	Use of vena cava filters in cancer patients in California. <i>Thrombosis Research</i> , 2012, 129, S161-S162.	1.7	0
121	Severity-of-illness in cancer patients contributes to the risk of hospital-acquired venous thromboembolism (VTE), but not post-discharge VTE. <i>Thrombosis Research</i> , 2012, 129, S166-S167.	1.7	0
122	Risk assessment models for cancer-associated venous thromboembolism. <i>Cancer</i> , 2012, 118, 3468-3476.	4.1	33
123	Pan-Selectin Antagonist GMI-1070 Affects Biomarkers of Adhesion, Activation and the Coagulation Cascade in Sickle Cell Adults At Steady State. <i>Blood</i> , 2012, 120, 87-87.	1.4	1
124	Increased Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor (sLOX-1) and Increased Endothelial Cell Expression of LOX-1 in Sickle Cell Disease (SCD): A Novel Marker for SCD Vasculopathy?. <i>Blood</i> , 2012, 120, 246-246.	1.4	0
125	Monocyte Chemotactic Protein-1 Is Associated with Microvascular Abnormalities and Serum Ferritin Concentrations in Sickle Cell Disease Patients. <i>Blood</i> , 2012, 120, 3255-3255.	1.4	0
126	A method to identify California's sickle-cell disease population and its linkage to the California Cancer Registry. <i>Journal of Registry Management</i> , 2012, 39, 53-61.	0.1	1

#	ARTICLE	IF	CITATIONS
127	Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease. <i>British Journal of Haematology</i> , 2011, 155, 263-267.	2.5	34
128	Cancer Health Empowerment for Living without Pain (Ca-HELP): effects of a tailored education and coaching intervention on pain and impairment. <i>Pain</i> , 2011, 152, 1572-1582.	4.2	59
129	Splenectomy and the Incidence of Venous Thromboembolism and Sepsis In Patients with Immune Thrombocytopenia,. <i>Blood</i> , 2011, 118, 3284-3284.	1.4	1
130	A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 847-847.	1.4	5
131	Inhibition of E-Selectin Inflammatory Function by the Glycomimetic GMI-1070. <i>Blood</i> , 2011, 118, 851-851.	1.4	3
132	Incidence and Risk Factors for Intracranial Hemorrhage in Californians with Immune Thrombocytopenia. <i>Blood</i> , 2011, 118, 1161-1161.	1.4	0
133	Increased Incidence of Hematological Malignancies Among Californians with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 1073-1073.	1.4	0
134	Biomarkers of Hemostatic Activation in a Randomized, Double-Blind, Phase 2 Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 2127-2127.	1.4	0
135	Mightier than the sickle cell. <i>Blood</i> , 2010, 116, 1633-1633.	1.4	2
136	The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. <i>Cancer</i> , 2010, 116, 2596-2603.	4.1	49
137	Comparison of real-time microvascular abnormalities in pediatric and adult sickle cell anemia patients. <i>American Journal of Hematology</i> , 2010, 85, 899-901.	4.1	32
138	Recurrent venous thromboembolism after surgery-provoked versus unprovoked thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 987-997.	3.8	28
139	Emergency Department Sickle Cell Assessment of Needs and Strengths (ED-SCANS), a Focus Group and Decision Support Tool Development Project. <i>Academic Emergency Medicine</i> , 2010, 17, 848-858.	1.8	15
140	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. <i>Thrombosis Research</i> , 2010, 125, S96-S102.	1.7	40
141	GMI-1070, a Pan-Selectin Inhibitor: Safety and PK In a Phase 1/2 Study In Adults with Sickle Cell Disease. <i>Blood</i> , 2010, 116, 1632-1632.	1.4	6
142	Effects of GMI-1070, a Pan-Selectin Inhibitor, on Leukocyte Adhesion In Sickle Cell Disease: Results From a Phase 1/2 Study. <i>Blood</i> , 2010, 116, 262-262.	1.4	4
143	Identification of Novel Peptide Ligands Targeting $\alpha 4 \beta 1$ Integrins on Patient Lymphoma Cells. <i>Blood</i> , 2010, 116, 4854-4854.	1.4	0
144	Effects of Selectin Antagonist GMI-1070 on the Activation State of Leukocytes In Sickle Cell Patients Not In Crisis. <i>Blood</i> , 2010, 116, 2672-2672.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Best practices for transfusion for patients with sickle cell disease. <i>Hematology Reports</i> , 2009, 1, 22.	0.8	8
146	Venous Thromboembolism (VTE) in Patients with Cancer: Epidemiology and Risk Factors. <i>Cancer Investigation</i> , 2009, 27, 63-74.	1.3	150
147	Cancer Health Empowerment for Living without Pain (Ca-HELP): study design and rationale for a tailored education and coaching intervention to enhance care of cancer-related pain. <i>BMC Cancer</i> , 2009, 9, 319.	2.6	18
148	UC Davis CTSA: Coming of Age. <i>Clinical and Translational Science</i> , 2009, 2, 98-101.	3.1	3
149	A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. <i>Cytometry Part B - Clinical Cytometry</i> , 2009, 76B, 159-168.	1.5	59
150	Jumpstarting Academic Careers with a Novel Intern Research Rotation: the AIMS Rotation. <i>American Journal of Medicine</i> , 2009, 122, 1061-1066.	1.5	9
151	Epidemiology of cancer-related venous thromboembolism. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 9-23.	1.7	193
152	Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. <i>Blood</i> , 2009, 113, 3911-3917.	1.4	141
153	Overcoming barriers to cancer clinical trial accrual. <i>Cancer</i> , 2008, 112, 212-219.	4.1	64
154	The incidence of venous thromboembolism among patients with primary lung cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 601-608.	3.8	247
155	Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS): a 24-year clinical experience with 178 patients. <i>Journal of Hematology and Oncology</i> , 2008, 1, 23.	17.0	35
156	Positron Emission Tomography and Improved Survival in Patients With Lung Cancer_{title>}The Will Rogers Phenomenon Revisited</sub>. <i>Archives of Internal Medicine</i> , 2008, 168, 1541.	3.8	90
157	Positron emission tomography (PET) and improved survival in non-small cell lung cancer (NSCLC) patients: The Will Rogers Phenomenon revisited. <i>Journal of Clinical Oncology</i> , 2008, 26, 11038-11038.	1.6	0
158	Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. <i>Journal of Neurosurgery</i> , 2007, 106, 601-608.	1.6	236
159	Usefulness of Optical Density Values From Heparin-Platelet Factor 4 Antibody Testing and Probability Scoring Models to Diagnose Heparin-Induced Thrombocytopenia. <i>American Journal of Clinical Pathology</i> , 2007, 127, 429-433.	0.7	42
160	Targeting patients for anticoagulant prophylaxis trials in patients with cancer: Who is at highest risk?. <i>Thrombosis Research</i> , 2007, 120, S29-S40.	1.7	42
161	PO-95 Venous thromboembolism (VTE) is associated with recurrent cancer in patients with initially non-metastatic breast, lung, and colon cancer. <i>Thrombosis Research</i> , 2007, 120, S175.	1.7	2
162	Venous thromboembolism in ovarian cancer. <i>Gynecologic Oncology</i> , 2007, 105, 784-790.	1.4	136

#	ARTICLE	IF	CITATIONS
163	A Novel PF4-Heparin Microbead Assay and Plasma Protein Biomarker Profiling for Improved Diagnosis of Heparin Induced Thrombocytopenia.. Blood, 2007, 110, 3216-3216.	1.4	0
164	Low-dose warfarin does not decrease the rate of thrombosis in patients with cervix and vulvo-vaginal cancer treated with chemotherapy, radiation, and erythropoietin. Gynecologic Oncology, 2006, 102, 98-102.	1.4	21
165	Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 314-321.	0.3	10
166	Venous Thromboembolism in Patients With Colorectal Cancer: Incidence and Effect on Survival. Journal of Clinical Oncology, 2006, 24, 1112-1118.	1.6	325
167	Incidence of Venous Thromboembolism in Patients with Acute Leukemia.. Blood, 2006, 108, 1497-1497.	1.4	15
168	Cause of Death among Patients with Local or Regional Stage Cancer of the Breast, Colon and Lung Who Develop Venous Thromboembolism (VTE).. Blood, 2006, 108, 1501-1501.	1.4	2
169	Venous thromboembolism in 9,489 patients with glioma. Journal of Clinical Oncology, 2006, 24, 1538-1538.	1.6	0
170	Impact of a mass media campaign (MMC) on awareness of and willingness to participate in cancer clinical trials (CCT): Results from 2,269 survey respondents. Journal of Clinical Oncology, 2006, 24, 6012-6012.	1.6	0
171	Utility of Optical Density Values from Heparin-Platelet Factor 4 Antibody Testing and Probability Scoring Models To Diagnose Patients with Heparin Induced Thrombocytopenia.. Blood, 2006, 108, 1475-1475.	1.4	0
172	Evaluation of Factors Affecting Awareness of and Willingness to Participate in Cancer Clinical Trials. Journal of Clinical Oncology, 2005, 23, 9282-9289.	1.6	123
173	High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody. Clinical Cancer Research, 2005, 11, 5920-5927.	7.0	87
174	Awareness among oncology providers and financial counselors of a California law requiring third-party payer coverage of cancer clinical Trial (CCT) Costs. Journal of Clinical Oncology, 2005, 23, 6111-6111.	1.6	0
175	Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. Journal of Rheumatology, 2005, 32, 2109-15.	2.0	56
176	Acute myocardial infarction in hemoglobin SC disease. Annals of Hematology, 2004, 83, 622-4.	1.8	8
177	Increased cyclooxygenase-2 (COX-2): a potential role in the pathogenesis of lymphoma. Leukemia Research, 2004, 28, 179-190.	0.8	85
178	Inflammatory potential of neutrophils detected in sickle cell disease. American Journal of Hematology, 2004, 76, 126-133.	4.1	66
179	Effects of Poloxamer 188 Treatment on Sickle Cell Vaso-occlusive Crisis: Computer-Assisted Intravital Microscopy Study. Journal of Investigative Medicine, 2004, 52, 402-406.	1.6	25
180	Combined modality radioimmunotherapy (RIT) in metastatic prostate (PC) and breast cancer (BC) using paclitaxel (PT) and a MUC-1 monoclonal antibody, m170, linked to yttrium-90 (Y-90): A phase I trial. Journal of Clinical Oncology, 2004, 22, 2554-2554.	1.6	6

#	ARTICLE	IF	CITATIONS
181	Incidence of symptomatic venous thrombosis in cervical and vulvo-vaginal carcinoma treated with concurrent chemoradiation, erythropoietin, and coumadin. <i>Journal of Clinical Oncology</i> , 2004, 22, 8101-8101.	1.6	0
182	The Incidence and Timing of Unprovoked Venous Thromboembolism Prior to the Diagnosis of Common Cancers.. <i>Blood</i> , 2004, 104, 2582-2582.	1.4	5
183	Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. <i>Cancer</i> , 2003, 98, 1514-1520.	4.1	135
184	Microvascular abnormalities in sickle cell disease: a computer-assisted intravital microscopy study. <i>Blood</i> , 2002, 99, 3999-4005.	1.4	87
185	The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function. <i>Thrombosis Research</i> , 2002, 106, 191-197.	1.7	169
186	Acetaminophen and diphenhydramine as premedication for platelet transfusions: A prospective randomized double-blind placebo-controlled trial. <i>American Journal of Hematology</i> , 2002, 70, 191-194.	4.1	88
187	Filgrastim Treatment of Acute Myelogenous Leukemia (M7) Relapse after Allogeneic Peripheral Stem Cell Transplantation Resulting in Both Graft-versus-Leukemia Effect with Cytogenetic Remission and Chronic Graft-versus-Host Disease Manifesting as Polyserositis and Subsequent Bronchiolitis Obliterans with Organizing Pneumonia. <i>International Journal of Hematology</i> , 2002, 76, 360-364.	1.6	7
188	Isolated cavernous sinus extramedullary relapse of chronic myelogenous leukemia following allogeneic stem cell transplant. <i>Annals of Hematology</i> , 2002, 81, 108-110.	1.8	10
189	Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease*. <i>International Journal of Laboratory Hematology</i> , 2002, 24, 81-88.	0.2	58
190	Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease*. <i>International Journal of Laboratory Hematology</i> , 2002, 24, 81-88.	0.2	91
191	The reply:. <i>American Journal of Medicine</i> , 2001, 110, 156-157.	1.5	1
192	Radioimmunotherapy. <i>BioDrugs</i> , 2001, 15, 151-162.	4.6	11
193	Prospective Evaluation of Cancer Clinical Trial Accrual Patterns: Identifying Potential Barriers to Enrollment. <i>Journal of Clinical Oncology</i> , 2001, 19, 1728-1733.	1.6	522
194	Correlation of abnormal intracranial vessel velocity, measured by transcranial Doppler ultrasonography, with abnormal conjunctival vessel velocity, measured by computer-assisted intravital microscopy, in sickle cell disease. <i>Blood</i> , 2001, 97, 3401-3404.	1.4	34
195	Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. <i>Leukemia</i> , 2001, 15, 208-216.	7.2	47
196	Purified Poloxamer 188 for Treatment of Acute Vaso-occlusive Crisis of Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2001, 286, 2099.	7.4	173
197	The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease; Haemoglobinopathy. <i>Hematology</i> , 2001, 5, 403-412.	1.5	22
198	The Role of Inflammation and Leukocytes in the Pathogenesis of Sickle Cell Disease. <i>Hematology</i> , 2000, 5, 403-412.	1.5	57

#	ARTICLE	IF	CITATIONS
199	Cocoa inhibits platelet activation and function. American Journal of Clinical Nutrition, 2000, 72, 30-35.	4.7	319
200	Cocoa and Wine Polyphenols Modulate Platelet Activation and Function. Journal of Nutrition, 2000, 130, 2120S-2126S.	2.9	155
201	Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. American Journal of Medicine, 1999, 107, 573-579.	1.5	92
202	Platelet-erythrocyte adhesion in sickle cell disease. Journal of Investigative Medicine, 1999, 47, 121-7.	1.6	34
203	Platelet activation in patients with sickle cell disease. British Journal of Haematology, 1998, 100, 741-749.	2.5	117
204	Platelet activation during dobutamine stress echocardiography. American Heart Journal, 1998, 135, 888-900.	2.7	21
205	Vasopressin and platelets: a concise review. Platelets, 1997, 8, 15-22.	2.3	16
206	Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. Translational Research, 1997, 129, 507-516.	2.3	135
207	Thrombopoietin is synergistic with other hematopoietic growth factors and physiologic platelet agonists for platelet activation in vitro. American Journal of Hematology, 1997, 54, 225-232.	4.1	37
208	Physiologic concentrations of arginine vasopressin activate human platelets in vitro. British Journal of Haematology, 1996, 92, 968-972.	2.5	54
209	Desmopressin stimulates the expression of P-selectin on human platelets in vitro. Translational Research, 1995, 126, 401-9.	2.3	25
210	Prolonged circulation of activated platelets following plasmapheresis. Journal of Clinical Apheresis, 1994, 9, 10-16.	1.3	32
211	Removal by white cell-reduction filters of activated platelets expressing CD62. Transfusion, 1993, 33, 930-935.	1.6	29
212	Early manifestation of thrombotic thrombocytopenic purpura. American Journal of Medicine, 1993, 95, 544-545.	1.5	10
213	The Felty Syndrome and G-CSF-Associated Thrombocytopenia and Severe Anemia. Annals of Internal Medicine, 1993, 118, 318.	3.9	20
214	Detection of plasmapheresis-induced platelet activation using monoclonal antibodies. Transfusion, 1992, 32, 534-540.	1.6	32
215	Clonal remission in aplastic anemia after treatment with antithymocyte globulin. American Journal of Hematology, 1992, 40, 229-231.	4.1	4
216	Assessment of bleeding risk in the patient with no history of hemostatic problems. , 0, , 219-229.		0

#	ARTICLE	IF	CITATIONS
217	Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults. <i>Current Epidemiology Reports</i> , 0, , 1.	2.4	0